217314-47-1

Basic information

• Product Name: METHYL 3-AMINO-5-METHOXYBENZOATE
• Synonyms: METHYL 3-AMINO-5-METHOXYBENZOATE;Benzoic acid,3-aMino-5-Methoxy-, Methyl ester
• CAS NO: 217314-47-1
• Molecular Formula: C₉H₁₁NO₃
• Molecular Weight: 181.19
• Mol File: 217314-47-1.mol

Chemical Properties

• Boiling Point: 335.219 °C at 760 mmHg
• Flash Point: 178.301 °C
• Appearance: /
• Density: 1.18 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 3.03±0.10(Predicted)
• CAS DataBase Reference: METHYL 3-AMINO-5-METHOXYBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-AMINO-5-METHOXYBENZOATE(217314-47-1)
• EPA Substance Registry System: METHYL 3-AMINO-5-METHOXYBENZOATE(217314-47-1)

Safety Data

• Hazardous Substances Data: 217314-47-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 3-AMINO-5-METHOXYBENZOATE is used as an intermediate in the synthesis of various drugs, contributing to the development of new medications and improving existing ones.
Used in Agrochemical Industry:
METHYL 3-AMINO-5-METHOXYBENZOATE is utilized in the manufacturing of agrochemicals, playing a role in the development of pesticides and other agricultural products to enhance crop protection and yield.
Used in Food Industry:
METHYL 3-AMINO-5-METHOXYBENZOATE is employed as a flavoring agent, adding unique taste profiles to food products while ensuring safety and quality standards are met.
It is crucial to handle and store METHYL 3-AMINO-5-METHOXYBENZOATE according to safety guidelines and regulations due to its potential health and environmental hazards.

Upstream product

• 67-56-1 methanol 
• 74165-74-5 3-amino-5-methoxybenzoic acid 
• 78238-13-8 3-methoxy-5-nitrobenzoic acid methyl ester 
• 217314-45-9 methyl 3-amino-5-iodobenzoate 
• 217314-43-7 1-(3-methoxy-5-methoxycarbonylphenyl)-2,5-dimethyl-1H-pyrrole 

Downstream Products

• 220965-92-4 3-<<<3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl>carbonyl>amino>-5-methoxybenzoic acid, methyl ester 
• 1375152-12-7 C₁₅H₁₅NO₅S 
• 1375214-08-6 C₁₂H₁₆ClNO₅S 
• 717109-27-8 methyl 3-iodo-5-methoxybenzoate 
• 1346245-88-2 C₂₀H₁₇N₅O₂ 
• 1261566-52-2 (3-amino-5-methoxyphenyl)methanol 
• 1346245-87-1 C₂₀H₁₉N₅O₂ 
• 1346245-89-3 C₂₄H₂₈N₆O 
• 1017240-74-2 3-methoxy-5-(2-oxopyrrolidin-1-yl)benzoic acid 
• 1375152-04-7 C₁₀H₁₃NO₅S 
• 220965-93-5 3-<<<3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl>carbonyl>amino>-5-methoxybenzoic acid 
• 1003857-96-2 3-methoxy-5-pent-4-enylamino-benzoic acid methyl ester 

Relevant articles and documents

New diarylsulfonamide inhibitors of Leishmania infantum amastigotes

New drugs against visceral leishmaniasis with mechanisms of action differing from existing treatments and with adequate cost, stability, and properties are urgently needed. No antitubulin drug is currently in the clinic against Leishmania infantum, the causative agent of visceral leishmaniasis in the Mediterranean area. We have designed and synthesized a focused library of 350 compounds against the Leishmania tubulin based on the structure-activity relationship (SAR) and sequence differences between host and parasite. The compounds synthesized are accessible, stable, and appropriately soluble in water. We assayed the library against Leishmania promastigotes, axenic, and intracellular amastigotes and found 0, 8, and 16 active compounds, respectively, with a high success rate against intracellular amastigotes of over 10%, not including the cytotoxic compounds. Five compounds have a similar or better potency than the clinically used miltefosine. 14 compounds showed a host-dependent mechanism of action that might be advantageous as it may render them less susceptible to the development of drug resistance. The active compounds cluster in five chemical classes that provide structure-activity relationships for further hit improvement and facilitate series development. Molecular docking is consistent with the proposed mechanism of action, supported by the observed structure-activity relationships, and suggests a potential extension to other Leishmania species due to sequence similarities. A new family of diarylsulfonamides designed against the parasite tubulins is active against Leishmania infantum and represents a new class of potential drugs with favorable cost, stability, and aqueous solubility for the treatment of visceral leishmaniasis (VL). These results could be extended to other clinically relevant species of Leishmania spp.

Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor

Monoacylglycerol lipase (MAGL) is the enzyme degrading the endocannabinoid 2-arachidonoylglycerol, and it is involved in several physiological and pathological processes. The therapeutic potential of MAGL is linked to several diseases, including cancer. The development of MAGL inhibitors has been greatly limited by the side effects associated with the prolonged MAGL inactivation. Importantly, it could be preferable to use reversible MAGL inhibitors in vivo, but nowadays only few reversible compounds have been developed. In the present study, structural optimization of a previously developed class of MAGL inhibitors led to the identification of compound 23, which proved to be a very potent reversible MAGL inhibitor (IC50 = 80 nM), selective for MAGL over the other main components of the endocannabinoid system, endowed of a promising antiproliferative activity in a series of cancer cell lines and able to block MAGL both in cell-based as well as in vivo assays.

KINASE INHIBITORS

There are provided compounds of formula I, wherein T, A, Q, Z, G, R4, R5a, R5b and n have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members

PYRAZOLYL QUINAZOLINE KINASE INHIBITORS

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS

The invention relates to novel macrocyclic compounds of the Formula (I) in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS

Compounds of formula I wherein R and R1 are as defined in the description.The compounds of formula I are PDE 4 inhibitors.

Heterogeneous foldamers containing alpha, beta, and/or gamma-amino acids

Disclosed are isolated, unnatural polypeptides containing cyclically-constrained β-amino acid residues and cyclically-constrained γ-amino acid residues. The compounds are unnatural and because they contain rotationally constrained residues that are not amenable to enzymatic degradation, the compounds are useful to probe protein-protein and other large molecule interactions.

ASPARTYL PROTEASE INHIBITORS

The present invention provides compounds having formula (I): wherein R’, R0, R1, X1, R2, R3, R3’, X2, X3, and R4 are as defined herein, and pharmaceuticals compositions thereof. The present invention also provides methods of inhibiting proteases, more specially aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer’s Disease). The present invention also provides methods for preparing compounds of the invention.

2,5-dimethylpyrrole protection facilitates copper(I)-mediated methoxylations of aryl iodides in the presence of anilines

Converting iodoanilines to the corresponding 2,5-dimethylpyrroles was found to facilitate CuCI-mediated methoxide substitution. Examples with ortho-, meta-, or para-relationships between the iodide and aniline are presented. Several other aniline blocking groups were investigated and found not to be successful in this sequence.